Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
B7H3 CAR-T Cell Therapy in B7H3-Positive Solid Tumors
NCT07152236Withdrawn
- Sponsor
- Guangzhou Bio-gene Technology Co., Ltd.
- Start
- Aug 2025
- Primary completion
- Mar 2026
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Open-label, single-arm trial of B7H3 CAR-T in solid tumor, sponsored by Guangzhou Bio-gene Technology Co., Ltd. Primary endpoints: Evaluation of Safety at 1 year and Effectiveness evaluation at 1 year. Planned start Aug 2025; status: withdrawn.
02
Drugs
B7H3 CAR-T
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT07152236.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07152236.